

TDMS No. 20201 - 03
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PECDF)
CAS Number: 57117-31-4

Date Report Reqsted: 06/14/2006
Time Report Reqsted: 15:27:08
First Dose M/F: NA / 04/21/03
Lab: BAT

C Number: C20201C
Lock Date: 07/24/2004
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL

TDMS No. 20201 - 03
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PECDF)
CAS Number: 57117-31-4

Date Report Requested: 06/14/2006
Time Report Requested: 15:27:08
First Dose M/F: NA / 04/21/03
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
Disposition Summary					
Animals Initially in Study	20	20	20	20	20
Early Deaths					
Moribund Sacrifice	1	4	3	7	6
Natural Death	2	3	1		1
Survivors					
Moribund Sacrifice					1
Terminal Sacrifice	17	13	16	13	12
Animals Examined Microscopically	20	20	20	20	20
ALIMENTARY SYSTEM					
Liver	(20)	(20)	(20)	(20)	(20)
Clear Cell Focus	1 (5%)				
Degeneration			1 (5%)	1 (5%)	2 (10%)
Fatty Change	1 (5%)	2 (10%)	1 (5%)	11 (55%)	3 (15%)
Hematopoietic Cell Proliferation	1 (5%)	1 (5%)	4 (20%)	10 (50%)	15 (75%)
Hepatodiaphragmatic Nodule	1 (5%)				
Inflammation	19 (95%)	18 (90%)	20 (100%)	18 (90%)	13 (65%)
Myelodysplasia					1 (5%)
Necrosis	7 (35%)	5 (25%)	7 (35%)	8 (40%)	6 (30%)
Pigmentation	10 (50%)	8 (40%)	13 (65%)	11 (55%)	10 (50%)
Vein, Thrombosis			1 (5%)		
Mesentery	(1)	(1)	(0)	(0)	(0)
Fat, Necrosis	1 (100%)	1 (100%)			
Pancreas	(0)	(1)	(0)	(0)	(0)
Cyst		1 (100%)			
Salivary Glands	(1)	(0)	(0)	(0)	(0)
Stomach, Forestomach	(6)	(2)	(2)	(5)	(8)
Stomach, Glandular	(1)	(0)	(0)	(0)	(0)
Glands, Hyperplasia	1 (100%)				
Tooth	(6)	(6)	(3)	(1)	(2)
Malformation				1 (100%)	
CARDIOVASCULAR SYSTEM					
Heart	(0)	(0)	(0)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 03
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PECDF)
CAS Number: 57117-31-4

Date Report Requested: 06/14/2006
Time Report Requested: 15:27:08
First Dose M/F: NA / 04/21/03
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
Thrombosis					1 (100%)
ENDOCRINE SYSTEM					
Pituitary Gland Cyst	(0)	(0)	(1) 1 (100%)	(1)	(0)
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOPOIETIC SYSTEM					
Lymph Node	(0)	(0)	(0)	(8) 4 (50%)	(4)
Hyperplasia, Lymphoid				1 (13%)	
Hyperplasia, Plasma Cell				2 (25%)	
Inflammation				(3)	(3)
Lymph Node, Mandibular	(0)	(1)	(0)	1 (33%)	2 (67%)
Hyperplasia, Lymphoid					
Hyperplasia, Oncocytic		1 (100%)			
Inflammation				1 (33%)	
Lymph Node, Mesenteric	(1)	(1)	(0)	(2)	(1)
Hyperplasia, Lymphoid		1 (100%)		2 (100%)	
Spleen	(20)	(20)	(20)	(20)	(20)
Hematopoietic Cell Proliferation	3 (15%)	7 (35%)	13 (65%)	14 (70%)	14 (70%)
Myelodysplasia					1 (5%)
Thymus	(20)	(19)	(19)	(19)	(18)
Atrophy	3 (15%)	3 (16%)	6 (32%)	6 (32%)	12 (67%)
INTEGUMENTARY SYSTEM					
Skin	(4)	(4)	(8)	(7)	(13)
Cyst Epithelial Inclusion			1 (13%)		
Fibrosis	1 (25%)		1 (13%)	1 (14%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 03

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

TEF TRANSGENICS (PECDF)

CAS Number: 57117-31-4

Date Report Requested: 06/14/2006

Time Report Requested: 15:27:08

First Dose M/F: NA / 04/21/03

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
Hyperplasia, Mast Cell					1 (8%)
Hyperplasia, Squamous	4 (100%)	1 (25%)	4 (50%)	3 (43%)	3 (23%)
Inflammation, Chronic Active	3 (75%)	1 (25%)	3 (38%)	6 (86%)	10 (77%)
Ulcer	1 (25%)				
Skin, Control Dermis	(20)	(20)	(20)	(20)	(20)
Inflammation, Chronic Active			1 (5%)	5 (25%)	1 (5%)
Skin, Control Epidermis	(20)	(20)	(20)	(20)	(20)
Hyperplasia, Squamous				1 (5%)	
Skin, Site Of Application	(20)	(20)	(20)	(20)	(20)
Fibrosis	1 (5%)				
Hyperplasia, Mast Cell			1 (5%)		1 (5%)
Hyperplasia, Squamous	1 (5%)	8 (40%)	10 (50%)	18 (90%)	16 (80%)
Inflammation, Chronic Active	2 (10%)	14 (70%)	18 (90%)	20 (100%)	20 (100%)
Skin, Soa No Mass	(20)	(20)	(17)	(13)	(12)
Hyperplasia, Mast Cell		1 (5%)			
Hyperplasia, Squamous	1 (5%)	6 (30%)	8 (47%)	9 (69%)	6 (50%)
Inflammation, Chronic Active	3 (15%)	6 (30%)	11 (65%)	12 (92%)	9 (75%)
Ulcer				1 (8%)	
MUSCULOSKELETAL SYSTEM					
None					
NERVOUS SYSTEM					
None					
RESPIRATORY SYSTEM					
Lung	(20)	(20)	(20)	(20)	(20)
Alveolar Epithelium, Hyperplasia				1 (5%)	1 (5%)
Alveolus, Infiltration Cellular, Histiocyte		1 (5%)	1 (5%)	3 (15%)	1 (5%)
Interstitial, Inflammation	1 (5%)	1 (5%)	1 (5%)		5 (25%)
Perivascular, Inflammation	2 (10%)			2 (10%)	1 (5%)
Serosa, Inflammation, Chronic Active	7 (35%)		1 (5%)	7 (35%)	2 (10%)
SPECIAL SENSES SYSTEM					
None					

a - Number of animals examined microscopically at site and number of animals with lesion

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 03
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
TEF TRANSGENICS (PECDF)
CAS Number: 57117-31-4

Date Report Reqsted: 06/14/2006
Time Report Reqsted: 15:27:08
First Dose M/F: NA / 04/21/03
Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	72 NG/KG	242 NG/KG	720 NG/KG	1520 NG/KG
URINARY SYSTEM					
Kidney	(0)	(0)	(0)	(0)	(1)

*** END OF REPORT ***